Setmelanotide
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Rhythm · Phase 3 · Completed · Enrollment 19
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.